New eye drug could mean fewer shots for PCV patients

NCT ID NCT07461441

Recruiting now Disease control Sponsor: Yeungnam University College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests faricimab (Vabysmo) in 50 people with a type of age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can keep the eye healthy while allowing longer breaks between injections—up to 16 weeks or more. Participants receive the drug as an eye injection, and the study tracks vision and retinal thickness over 96 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: faricimab (Vabysmo)
What this could lead to: If successful, this could allow people with PCV to receive eye injections less often (every 16 weeks or more) while maintaining vision.
What could go wrong: This is a small Phase 3 trial (50 people) and results may not apply to all patients. Faricimab injections carry risks like eye infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration Polypoidal Choroidal Vasculopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Yeungnam university medical center
RECRUITING

Daegu, Namgu, 42415, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.